Fourteen neutralizing monoclonal antibodies recognizing human rhinovirus (HRV) type 2 have been used to select a total of 51 virus escape mutants. Crossresistance analysis of the mutants, together with RNA sequencing and identification of amino acid substi-tutions, have revealed three neutralization sites on the virus surface. Two of these appear to correspond to the NIm-IA and NIm-II sites described for HRV-type 14, although there are also substantial differences. The third site has not been described previously.
Introduction
Rhinoviruses, the major causative agents of common colds (Stott & Killington, 1972) , are important human pathogens. Indeed it has been suggested that rhinovirus infections may be the most common of all the acute infections of man (Gwaltney, 1975) . The viruses show extreme antigenic variation, with over a hundred serotypes differentiated by neutralization tests (Hamparian et al., 1987) . In addition they may be divided into major and minor subgroups with respect to their specificity for cell receptors (Abraham & Colonno, 1984) . This diversity poses special problems for vaccine design. A better understanding of the antigenic sites that mediate the neutralization of rhinoviruses should help to overcome these problems.
The human rhinovirus (HRV) particle consists of an icosahedral capsid enclosing a single strand of positivesense RNA. The virus surface is composed of a mosaic of 60 triads of the proteins VP1, VP2 and VP3; a fourth protein, VP4, is located internally. X-ray analysis of virus crystals has revealed the three-dimensional structure of HRV type 14 (HRV-14) to atomic resolution (Rossmann et al., 1985) and a map of the surface amino acid residues has been published (Rossmann & Palmenberg, 1988) . Recently, the crystal structure of another rhinovirus, HRV-1A, has also been determined (Kim et al., 1989) . The antigens concerned in the neutralization of HRV-14 have been investigated by sequence analysis of virus escape mutants selected with monoclonal antibodies (MAbs) Sherry et al., 1986) . Four antigenic sites, designated NIm-IA, NIm-IB, Nim-II and NIm-III, were identified as targets for neutralizing antibody and located on the virus surface.
HRV-14 has proved to be an atypical rhinovirus in that its nucleotide sequence is more similar to those of 0000-9381 © 1990 SGM polioviruses than other rhinovirus serotypes so far examined (Stanway et al., 1984; Callahan et al., 1985; Skern et al., 1985; Duechler et al., 1987; Hughes et al., 1988) . We have therefore studied the neutralization immunogens of another rhinovirus, HRV-2, employing an approach similar to that used for HRV-14. HRV-2 is a more typical rhinovirus in terms of its nucleotide sequence, and also differs from HRV-14 in belonging to the minor rather than the major rhinovirus receptor subgroup (Abraham & Colonno, 1984; Colonno et al., 1986) . The availability of the structural coordinates of HRV-1A (Kim et al., 1989) , also a member of the minor receptor group, and the similarity of its capsid protein sequences to those of HRV-2 have enabled us to map the locations of the HRV-2 neutralization immunogens onto the particle structure with some confidence. In this paper we show that there is some correspondence, and several differences, between the neutralization immunogens of HRV-2 and HRV-14
Methods
Virus HRV-2 was received from Dr D. A. J. Tyrrell, MRC Common Cold Unit, Salisbury, U.K. After three successive plaque purifications its identity was confirmed by neutralization with HRV-2-specific antiserum. The virus was grown at 34 °C in OH-5 cells, a cloned line of O-HeLa cells which was selected for high sensitivity to rhinoviruses. Virus growth medium consisted of Eagle's MEM supplemented with 2 % foetal calf serum (FCS) and 30 mM-magnesium chloride. Infectivity was titrated by plaque assay in cultures of OH-5 cells, using an overlay of Eagle's MEM, 2% FCS, 15 mM-magnesium chloride, 100 ~tg/ml DEAE~lextran and 0.6% agarose.
Production of hybridomas and MAbs. Two BALB/c mice were immunized by the intraperitoneal injection of 107 p.f.u./mouse of purified virus in phosphate-buffered saline (PBS) pH 7-2 on three occasions at 2 week intervals. After a further 6 weeks the mice were boosted with 5 × 107 p.f.u, of virus intraperitoneally and their spleens removed 3 days later. The spleen cells were fused with NS0 myeloma cells using polyethylene glycol 1500 (BDH) and the resulting hybridomas were cloned twice by limiting dilution. MAbs were produced by growing the hybridomas in RPMI 1640 supplemented with 5 % FCS. The class and subclass of each MAb were determined by the Ouchterlony diffusion technique using a commercially available kit (Serotec).
Neutralization assays. Virus at 3 × 105 p.f.u./ml in PBS plus 10%
(v/v) tryptose phosphate broth was incubated for 2 h at 36 °C with a range of dilutions of antibody and the infectivity of the mixture was titrated by plaque assay. The neutralization titre was taken as the reciprocal of the antibody dilution that reduced the virus plaque count by 90%. Alternatively, neutralizing activity was measured by a plaque inhibition test. Petri dish cultures of OH-5 cells were infected by the adsorption of about 100 p.f.u, of virus, overlaid with agarose medium containing a range of antibody dilutions and incubated at 34 °C for 3 days. High concentrations of antibody suppressed plaque formation completely and lower concentrations reduced the size of the plaques. The plaque inhibition titre was defined as the reciprocal of the dilution of antibody that reduced plaque diameter from about 4 mm (normal size) to about 1 mm (small but easily visible).
Isolation of neutralization-resistant escape mutants. OH-5 cell cultures
were overlaid with virus growth medium supplemented with the appropriate MAb and inoculated with 105 to 106 p.f.u, of HRV-2. After incubation at 34 °C for 3 days the resulting viruses were harvested and titrated with MAb in an agarose overlay, which allowed only neutralization-resistant virus to produce plaques of normal size. One such plaque was picked, the resistant virus was plaque-purified twice more and was finally grown in OH-5 cells. This procedure allowed us to select mutants using MAbs which had poor neutralization titres in conventional assays.
The first series of mutants were isolated from HRV-2 which had been cloned as described above; they were designated with the MAb number and the suffix R1. Subsequent mutants were isolated from four HRV-2 clones that were derived by separate plaque purifications of the original cloned stock; these were given the suffixes R2, R3, R4 or R5. This procedure ensured that mutants with different suffixes arose independently, even if selected with the same MAb; on the other hand, mutants selected with different MAbs but having the same suffix might on occasion be siblings.
Preparation of virus RNA. Virus RNA was obtained routinely from approximately 109 infected OH-5 cells grown in roller bottles. Cultures were infected at an m.o.i, of approximately 1 with either parental or MAb-selected virus. After 24 h at 34°C, the infected cells were harvested and virus was released by two cycles of freezing and thawing. The cell lysate was then clarified by centrifugation at 3000 r:p.m, for 10 min in a Sorvall GSA rotor and the virus was precipitated by addition of an equal volume of saturated ammonium sulphate in 0.1 ~-Tris-HC1 pH 7-5. After 1 to 2 h on ice, the virus was collected by centrifugation at 5000 r.p.m, for 10 min, also in the GSA rotor. The pellet was resuspended in 60 ml PBS containing 1% Sarkosyl plus 25 mM-HEPES pH 7-6 and recentrifuged at 33000 r.p.m, for 1.5 h in a Beckman T35 rotor. Finally the virus was purified by fractionation on a linear 15 to 45 % (w/v) sucrose gradient for 2.5 h at 28 000 r.p.m. The virus peak was detected spectrophotometrically, A26o, extracted twice with phenolchloroform, 0.5 % SDS, 0.1% 8-hydroxyquinoline, 0.3 M-sodium acetate pH 5.0 and precipitated with 2 volumes of ethanol. The RNA pellet was washed with 80 % ethanol and stored in diethyl pyrocarbonate-treated distilled water at -70 °C.
Sequencing of virus RNA. Sequencing was carried out by primer extension dideoxynucleotide chain termination directly from the virus RNA (Caton et al., 1982) using 1 btg RNA and synthetic deoxy- Skeru et al. (1985) .
nucleotide primers. The primers (Table 1) were designed using the published sequence of HRV-2 (Skern et al., 1985) and synthesized using an Applied Biosystems 381A DNA synthesizer. In general, the primers were chosen to cover those regions expected to represent major immunogenic sites on the virus based on known epitope mapping of HRV-14 (Sherry et al., 1986) 
Results

MAbs
Fourteen MAbs were produced against HRV-2 ( 
Neutralization escape mutants
Fifty-one neutralization-resistant mutants were selected with the 14 MAbs. Each mutant was tested for resistance to all MAbs by plaque inhibition; most of the results (including all positives) were confirmed by ELISA and many by direct neutralization tests. The patterns of resistance of 22 representative mutants are shown in Table 3 . Mutants not included in the table had neutralization properties identical to one or more of those shown. The results indicate that the MAbs, and the mutants selected by them, fall into three non-overlapping groups.
The first group contains only MAb 819. Mutants selected with this antibody were fully susceptible to all other MAbs, and the reverse was equally true. The largest group contains nine MAbs. Most of the antibodies can be differentiated from others in the group by at least one mutant; exceptions are the MAb pairs 806/ 825, 805/807 and possibly 801/829. The epitopes are all linked, directly or indirectly, because cross-resistant mutants were found. We conclude that these MAbs react with a single antigenic site that comprises at least six overlapping epitopes. MAbs 804, 810, 812 and 818 form a third group. These MAbs are not differentiated from each other by any of the mutants. They showed no crossresistance with other MAbs and therefore seem to be directed against a separate antigenic site. All four MAbs neutralized poorly in the conventional test, but they were active in plaque inhibition tests ( Table 2) .
The existence of three distinct groups of MAbs implies that there are three separate neutralization sites on the virus surface. These are marked A, B and C in Table 3 .
Sequence changes in escape mutants
The amino acids involved in conferring resistance to neutralization by specific MAbs were determined by direct genomic sequencing of the mutants. For each region of the genome that was analysed the corresponding region from the parental virus was also determined. These analyses revealed three point substitutions in our isolate of HRV-2 compared with the published sequence (Skern et al., 1985) . Two of the substitutions resulted in amino acid changes but one was silent (Table 4 ). Interestingly, one of these changes was located in a region of VP2 which we had previously shown to be a neutralization site for HRV-2 (Francis et al., 1987) , and it was found (results not shown) that anti-peptide serum directed towards this site could distinguish between our isolate and the original Vienna HRV-2.
The results of genomic sequencing (Table 5) indicated the presence of single amino acid changes in 32 mutant viruses. In only one variant (801R2) did we detect a second mutation, which was predicted to involve an internal amino acid and so was probably not responsible for the antigenic characteristics of this mutant. E  GAA  825R3  VPI  267  D  GAT  G  GGT  806R2  VP1  268  R  AGG  G  GGG  806R3  VP1  269  S  AGT  G  GGT  806R4  VP1  269  S  AGT  I  ATT  811RI  VPI  269  S  AGT  N  AAT  811R3  VP1  269  S  AGT  G  GGT  811 R4  VP 1  269  S  AGT  I  ATT  825R2  VP1  269  S  AGT  R  AGA  825R4  VP 1  269  S  AGT  I  ATT  805R1  VPI  276  T  ACC  I  ATC  805R2  VP1  276  T  ACC  A  GCC  808R1  VP1  276  T  ACC  I  ATC  807R2  VP1  278  P  CCA  T  ACA  822R4  VP2  163  N  AAT  Y  TAT  822R5  VP2  163  N  AAT  S  AGT  801R1  VP2  164  P  CCT  S  TCT  801R27  VP2  164  P  CCT  L  CTT  80lR4  VP2  164  P  CCT  L  CTT  801R5  VP2  164  P  CCT  L  CTT  829R2  VP2  164  P  CCT  L  CTT  805R3  VP3  59  D  GAC  G  GGC  807R1  VP3  59  D  GAC  G  GGC  Site C  812R1  VP2  236  A  GCA  E  GAA  804R1  VP2  238  N  AAC  K  AAA  804R3  VP2  238  N  AAC  K  AAA  810R2  VP2  238  N  AAC  K  AAG  818R1  VP2  238  N  AAC  K  AAA  801R2~ VP2 214 S TCA L TTA * Numbering is based on the published sequence and proteolytic cleavage sites of Skern et al. (1985) . AA, amino acid.
t Indicates double mutation of 801R2.
Location of antigenic sites on the virus surface
If we assume that all the amino acid substitutions occur Kim et al., 1989) but not for HRV-2. However, using the structural coordinates of HRV-1A and a published alignment of the amino acid sequences of the viruses (Palmenberg, 1989) , the positions of the altered amino acids on the surface of HRV-2 have been predicted (Fig. 1) . The figure differs from conventional surface residue plots, which normally present one complete icosahedral asymmetric unit, in that it shows the contiguous halves of two adjacent units. The positions at which amino acid substitutions occur are indicated by circles. No attempt has been made to represent the contribution of each residue to the surface of the virus.
Discussion
To avoid confusion, we have adopted in this paper the following definitions based on those of Wimmer et al. (1984) . The term epitope refers to that part of the virus surface, composed of contiguous or non-contiguous amino acids, to which a particular antibody binds. A sequential epitope is defined as depending only on the amino acid sequence of a part of a protein, whereas a conformational epitope depends on the spatial arrangement of the surface of a protein or proteins. A cluster of epitopes, in which each overlaps at least one other, defines an antigenic site. It follows that two apparently separate antigenic sites will only remain so for as long as no antibody is found to connect them. A site may be confined to a single capsid protein, or may be composed of parts of two or more proteins. The cross-resistance patterns of our escape mutants indicate that the neutralization of HRV-2 involves three antigenic sites, which have been named A, B and C. The predicted positions of these sites on the virus surface are shown in Fig. 1 .
Antigenic site A reacts with only one of our MAbs. It appears to be confined to VP1, between the fivefold symmetry axis and the canyon, and closely resembles the NIm-IA site of HRV-14. MAb 819, directed against this site, has particularly good neutralizing activity.
Antigenic site B is recognized by nine of the 14 MAbs and includes residues from all three surface proteins. The VP1 residues are split into two groups, one at each side of the basic icosahedral asymmetric unit. For this reason we feel that the smallest unit of the HRV-2 surface recognized by antibody is best represented by the kite shape of Fig. 1, which is formed by the adjacent halves of two icosahedral asymmetric units. Site B then appears as a single site overlapping the junction. As shown in Fig.  2 (a) , its VP 1 residues are part of a protein chain different from that forming site A. The VP2 region of site B, recognized by MAbs 822, 829 and 801, has been implicated previously in the neutralization of HRV-2. Skern et al. (1987) identified a neutralizing MAb, 8F5, for which the epitope lay within the amino acid sequence 153 to 164 of VP2. We have confirmed the location of this epitope by finding that the HRV-2 mutants 822R4, 822R5 and 801R1, with changes in amino acids 163 and 164, are resistant to neutralization by MAb 8F5 (results not shown). Further, Francis et al. (1987) have demonstrated that a peptide composed of amino acids 156 to 170 of VP2 can induce the formation of HRV-2-neutralizing antibody in rabbits.
VP3 contributes at least one residue to site B of HRV- G. Appleyard and others 2, since substitution of glycine for aspartic acid at position 59 confers resistance to neutralization in two mutants (Table 5 ). It may be of interest to note that the residues between positions 59 and 63 in VP3 of HRV-14 form a large protrusion on the surface, and yet the area has not previously been shown to be part of a neutralization site for a rhinovirus (Rossmann et al., 1985; . Our result is consistent with the finding that the equivalent area of poliovirus around residue 3059, located at the top of a small loop, is involved in neutralization (Page et al., 1988) . The VP2 region of site B overlaps the NIm-II site of HRV-14 (Sherry et al., 1986) . However, the protein contributing the most residues to NIm-II is VP2, whereas our results suggest that VP1 is the major contributor to site B. Also the NIm-II site of HRV-14 is situated entirely within a single icosahedral asymmetric unit, unlike site B of HRV-2 which overlaps two units as described above. Hence site B is only partly analogous to the NIm-II site of HRV-14.
Antigenic site C, recognized by four MAbs, includes two amino acids from VP2. This site does not appear to correspond to any of the sites described for HRV-14, although it is close to NIm-III. MAbs directed against site C are unusual in neutralizing poorly in conventional tests, even though they recognize virus in ELISAs and effectively suppress virus growth when incorporated into overlay medium (Table 2) .
The similarities between these HRV-2 sites and those of HRV-14 are also of interest. All are found in hypervariable regions of the proteins, not unexpectedly located at the highest points of the virus surface (Fig.  2b ). In addition, most sites include conformational epitopes. Evidence for that is provided by the finding that none of our MAbs react with HRV-2 proteins in Western blots (D. V. Sangar, personal communication), none show significant binding to a range of peptides whose sequences span the probable antigenic sites, and most epitopes in site B probably include amino acids from more than one protein.
In general, therefore, the antigenic sites revealed on HRV-2 by our panel of MAbs correspond to some extent with those found on HRV-14, but are not identical. The differences may reflect real diversity between two disparate rhinoviruses, or may merely be a reflection of the chance selection of MAbs. The examination of further rhinovirus serotypes may resolve this problem.
The validity of our approach to locating the neutralization sites on the virus surface depends upon the assumption that neutralization-resistant mutants arise by amino acid changes in the corresponding epitopes but not elsewhere. This question was discussed by Sherry et al. (1986) and they concluded that there was no evidence that any antigenic site in HRV-14 was affected by distant mutations. We have found only one amino acid substitution out of 33, a second change in variant 801R2 at position 214 of VP2 (Table 5) , which is not predicted to be on the virus surface (Fig. 2b) . It is probable that this change does not affect any antigenic site as the other change in this variant is sufficient to explain its resistance to neutralization. Table 6 shows the amino acid substitutions we have found (excluding the apparently random second mutation of 801R2), arranged in protein and sequence order, and their effects on the binding of the 14 MAbs. The data in Table 6 and Fig. 1 show that all those changes which prevent the binding of any given MAb occur within a 1 × 2 nm area of the virus surface. These dimensions are well within those determined by X-ray crystallographic techniques for the interface between lysozyme and antibody of 2 × 3 nm by Amit et al. (1986) and 1.9 x 2.6 nm by Sheriff et al. (1987) . In addition, the arrangement of epitopes on the virus surface deducible from the data in Fig. 1 and Table 6 is supported by the results of ELISA antibody blocking tests using biotin-labelled MAbs and captured HRV-2 antigen (Russell et al., 1989) . We conclude that our data are consistent with exclusively local effects of amino acid changes.
Another point is illustrated by Table 6 . Some residues are clearly parts of the epitopes of two or more MAbs. For example the serine at position 269 in VP1 forms part of the epitopes of MAbs 805,806, 807,808,811 and 825 in site B since its substitution by arginine confers resistance to all these MAbs. We have also found three other substitutions for this residue which can prevent antibody binding. A change to asparagine, isoleucine or glycine confers resistance to MAbs 806, 811 and 825 but not to the others. This is a clear demonstration that it cannot be assumed that a residue plays no part in antibody binding, or even that it is outside the epitope, just because a particular substitution does not confer resistance.
We have modelled the positions of the amino acid substitutions found in our HRV-2 mutants on the structural coordinates of HRV-1A. Although this indirect method is less satisfactory than the use of experimentally determined coordinates for HRV-2, it seems unlikely that the mutation sites shown in Fig. 1 are badly misplaced. The separation seen between the three antigenic sites and also the relative positions of individual epitopes of site B agree well with predictions from the cross-resistance data of Table 3 . Also, mapping the mutations onto a predicted HRV-2 structure gave a very similar picture. This model did, however, suggest that VP2 residues 164 and 238 are more accessible to antibody than is shown in Fig. 1 and Fig. 2 . Accurate placement of the residues substituted in the escape mutants must await a solution of the HRV-2 structure. It is possible that the analysis of further MAbs will extend or even link the sites described here. They may also allow an improved understanding of the interactions between virus and antibody. For example, none of the MAbs described here can neutralize, or even recognize, HRV-3, HRV-14 or HRV-49. Despite this, we have some evidence that MAbs recognizing more than one rhinovirus can be produced (Russell et al., 1989) . We hope to be able to define the epitopes of these MAbs and explore their relationship to those of the non-cross-reactive antibodies. These studies may assist in the future development of a broad spectrum rhinovirus vaccine.
